An Algorithm for Preclinical Diagnosis of Alzheimer's Disease

An Algorithm for Preclinical Diagnosis of Alzheimer's Disease

Almost all Alzheimer's disease (AD) therapeutic trials have failed in recent years. One of the main reasons for failure is due to designing the disease-modifying clinical trials at the advanced stage of the disease when irreversible brain damage has already occurred. Diagnosis of the preclinica...

Full description

Bibliographic Details
Main Author:	Tapan K. Khan
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2018-04-01
Series:	Frontiers in Neuroscience
Subjects:	Alzheimer's disease neuroimaging (anatomic and functional) CSF diagnosis differential preclinical Alzheimer's disease
Online Access:	http://journal.frontiersin.org/article/10.3389/fnins.2018.00275/full

Similar Items

Preclinical diagnosis of Alzheimer's disease: Prevention or prediction?
by: Ricardo Nitrini

Neuroimaging Modalities in Alzheimer’s Disease: Diagnosis and Clinical Features
by: JunHyun Kim, et al.
Published: (2022-05-01)

Early affective changes and increased connectivity in preclinical Alzheimer's disease
by: Carolyn A. Fredericks, et al.
Published: (2018-01-01)

TREML2 Mutation Mediate Alzheimer’s Disease Risk by Altering Neuronal Degeneration
by: Ya-Nan Song, et al.
Published: (2019-05-01)

Prevalence of abnormal Alzheimer’s disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samples
by: Steffen Wolfsgruber, et al.
Published: (2019-01-01)

Altered whole-brain white matter networks in preclinical Alzheimer's disease
by: Florian Udo Fischer, et al.
Published: (2015-01-01)

Considerations regarding a diagnosis of Alzheimer’s disease before dementia: a systematic review
by: Jetske van der Schaar, et al.
Published: (2022-02-01)

Lipid Peroxidation Assessment in Preclinical Alzheimer Disease Diagnosis
by: Carmen Peña-Bautista, et al.
Published: (2021-06-01)

Using the A/T/N Framework to Examine Driving in Preclinical Alzheimer’s Disease
by: Catherine M. Roe, et al.
Published: (2018-05-01)

Evaluation of Naturalistic Driving Behavior Using In-Vehicle Monitoring Technology in Preclinical and Early Alzheimer’s Disease
by: Jennifer D. Davis, et al.
Published: (2020-10-01)

Should artificial intelligence be used in conjunction with Neuroimaging in the diagnosis of Alzheimer’s disease?
by: Sophia Mirkin, et al.
Published: (2023-04-01)

Early Diagnosis of Alzheimer’s Disease Using Cerebral Catheter Angiogram Neuroimaging: A Novel Model Based on Deep Learning Approaches
by: Maha Gharaibeh, et al.
Published: (2021-12-01)

Change in retinal structural anatomy during the preclinical stage of Alzheimer's disease
by: Cláudia Y. Santos, et al.
Published: (2018-01-01)

Reactions to learning a “not elevated” amyloid PET result in a preclinical Alzheimer’s disease trial
by: Joshua D. Grill, et al.
Published: (2018-12-01)

CSF Biomarkers in the Early Diagnosis of Mild Cognitive Impairment and Alzheimer’s Disease
by: Vasileios Papaliagkas, et al.
Published: (2023-05-01)

Diagnostic Potential of Pulsed Arterial Spin Labeling In Alzheimer's Disease
by: Stefano eTrebeschi, et al.
Published: (2016-04-01)

Participant and study partner prediction and identification of cognitive impairment in preclinical Alzheimer’s disease: study partner vs. participant accuracy
by: Mary M. Ryan, et al.
Published: (2019-10-01)

The importance of the dyad: Participant perspectives on sharing biomarker results in Alzheimer's disease research
by: Fred B. Ketchum, et al.
Published: (2023-07-01)

Practice effects due to serial cognitive assessment: Implications for preclinical Alzheimer's disease randomized controlled trials
by: Terry E. Goldberg, et al.
Published: (2015-03-01)

P‐tau235: a novel biomarker for staging preclinical Alzheimer’s disease
by: Juan Lantero‐Rodriguez, et al.
Published: (2021-12-01)

Cognitively unimpaired individuals with a low burden of Aβ pathology have a distinct CSF biomarker profile
by: Marta Milà-Alomà, et al.
Published: (2021-07-01)

The meta-memory ratio: a new cohort-independent way to measure cognitive awareness in asymptomatic individuals at risk for Alzheimer’s disease
by: Geoffroy Gagliardi, et al.
Published: (2020-05-01)

Disruption of cholinergic neurotransmission, within a cognitive challenge paradigm, is indicative of Aβ-related cognitive impairment in preclinical Alzheimer’s disease after a 27-month delay interval
by: Jessica Alber, et al.
Published: (2020-03-01)

Neuroinflammatory CSF biomarkers MIF, sTREM1, and sTREM2 show dynamic expression profiles in Alzheimer’s disease
by: Yanaika S. Hok-A-Hin, et al.
Published: (2023-05-01)

Unsupervised mobile cognitive testing for use in preclinical Alzheimer's disease
by: Kathryn V. Papp, et al.
Published: (2021-01-01)

Cognitive reserve and lifestyle: moving towards preclinical Alzheimer’s disease
by: Eider M Arenaza-Urquijo, et al.
Published: (2015-08-01)

Neuroimaging in Alzheimer's disease: current role in clinical practice and potential future applications
by: Luiz Kobuti Ferreira, et al.
Published: (2011-01-01)

Is liquid biopsy mature enough for the diagnosis of Alzheimer’s disease?
by: Xun Gong, et al.
Published: (2022-08-01)

Driving assessment in preclinical Alzheimer’s disease: progress to date and the path forward
by: Sayeh Bayat, et al.
Published: (2022-11-01)

Asymmetric amyloid deposition in preclinical Alzheimer’s disease: A PET study
by: Pernille L. Kjeldsen, et al.
Published: (2022-01-01)

Improving preclinical to clinical translation in Alzheimer's disease research
by: Stacey J. Sukoff Rizzo, et al.
Published: (2020-01-01)

Nonvascular retinal imaging markers of preclinical Alzheimer's disease
by: Peter J. Snyder, et al.
Published: (2016-01-01)

Early-stage differentiation between Alzheimer’s disease and frontotemporal lobe degeneration: Clinical, neuropsychology, and neuroimaging features
by: Pan Li, et al.
Published: (2022-10-01)

Genetic risk and resilience for Alzheimer’s disease: The effect of the three APOE alleles on brain function across life
by: Suri, S
Published: (2016)

Current views of the risk factors, diagnosis, and therapy of Alzheimer's disease (according to the proceedings of the Alzheimer's Association International Conference, London, 2017)
by: N. N. Koberskaya
Published: (2017-11-01)

Phosphorylated Tau 181 Serum Levels Predict Alzheimer’s Disease in the Preclinical Stage
by: Wei Qin, et al.
Published: (2022-06-01)

Could Early Identification of Changes in Olfactory Function Be an Indicator of Preclinical Neurodegenerative Disease? A Systematic Review
by: Rikki L. Winchester, et al.
Published: (2020-06-01)

Sex-Related Disparities in the Resting State Functional Connectivity of the Locus Coeruelus and Salience Network in Preclinical Alzheimer’s Disease
by: Yoo Hyun Um, et al.
Published: (2023-10-01)

Regional pattern of beta-amyloid accumulation in the preclinical and clinical states of Alzheimer’s disease
by: A. G. Vlassenko, et al.
Published: (2017-02-01)

GPS driving: a digital biomarker for preclinical Alzheimer disease
by: Sayeh Bayat, et al.
Published: (2021-06-01)